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Interleukin-27 (IL-27) is a key immunosuppressive
cytokine that counters T helper 17 (Th17) cell-medi-
ated pathology. To identify mechanisms by which
IL-27 might exert its immunosuppressive effect, we
analyzed genes in T cells rapidly induced by IL-27.
We found that IL-27 priming of naive T cells upregu-
lated expression of programmed death ligand 1 (PD-
L1) in a signal transducer and activator of transcrip-
tion 1 (STAT1)-dependent manner. When cocultured
with naive CD4+ T cells, IL-27-primed T cells inhibited
the differentiation of Th17 cells in trans through a
PD-1-PD-L1 interaction. In vivo, coadministration
of naive TCR transgenic T cells (2D2 T cells) with
IL-27-primed T cells expressing PD-L1 inhibited
the development of Th17 cells and protected from
severe autoimmune encephalomyelitis. Thus, these
data identify a suppressive activity of IL-27, by which
CD4+ T cells can restrict differentiation of Th17 cells
in trans.
INTRODUCTION
Interleukin-27 (IL-27) is a member of a family of heterodimeric
cytokines with critical immunoregulatory properties (Cox et al.,
2011; Cua et al., 2003; Villarino et al., 2003). IL-27 was initially
identified as being important for inducing expression of T-bet
and enhancing Th1 cell differentiation. Later, it was appreciated
that IL-27, which shares the EBI3 subunit with IL-35, has essen-
tial, nonredundant immunosuppressive actions (Collison et al.,
2010; Owaki et al., 2005; Tong et al., 2010; Yoshida et al.,
2001). Specifically, mice lacking the IL-27 receptor (IL-27R)
develop lethal inflammation upon infection with a variety ofpathogens. For instance, during infection with Trypanosoma
cruzi, Il27ra/mice show severe pathological changes resulting
from enhanced Th1 and Th2 cell responses (Hamano et al.,
2003). Similarly, Il27ra/ mice infected with Toxoplasma gondii
develop uncontrolled tissue damage mediated by activated Th1
cells and increased IL-17 production (Stumhofer et al., 2006;
Villarino et al., 2003).
Various mechanisms of IL-27 have been suggested to explain
its immunosuppressive potency. IL-27 can directly inhibit inflam-
matory cytokine production in activated T cells in vitro (Villarino
et al., 2006; Yoshimura et al., 2006). In particular, IL-27 has
been suggested to diminish Th17 cell differentiation by inhibiting
the expression of RORgt (Diveu et al., 2009). In experimental
autoimmune encephalomyelitis (EAE), mice deficient in IL-27R
develop more severe Th17 cell-associated neuropathology,
whereas treatment of wild-type mice with IL-27 can constrain
Th17 cell differentiation and abolish development of EAE (Batten
et al., 2006; Fitzgerald et al., 2007).
In addition to inhibiting the production of IL-17, IL-27
enhances the production of the immunosuppressive cytokine
IL-10 in various T cell subsets (Batten et al., 2008; Diveu et al.,
2009; Stumhofer et al., 2007). Importantly, IL-27 works together
with TGF-b to drive the differentiation of IL-10-producing regula-
tory type 1 T cells (Tr1) through induction of aryl hydrocarbon
receptor (AhR), c-Maf, IL-21, and ICOS (Apetoh et al., 2010;
Awasthi et al., 2007; Murugaiyan et al., 2009; Pot et al., 2009).
IL-27 has also been reported to amplify TGF-b-induced FoxP3
expression in a STAT1-dependent manner (Ouaked et al.,
2009); however, other work has argued that IL-27 negatively
regulates FoxP3 expression (Neufert et al., 2007). Adoptive
transfer of Il27ra/ T cells was associated with reduced
pathology and enhanced Treg cell differentiation in a model of
autoimmune colitis (Cox et al., 2011).
IL-27 also has different effects on non-T cell lineages. For
instance, IL-27 can enhance IFN-g expression in NK cells
(Chiyo et al., 2005), whereas IL-27 can suppress LPS-induced
cytokine production by dendritic cells (DCs) in vitro. However,Immunity 36, 1017–1030, June 29, 2012 ª2012 Elsevier Inc. 1017
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IL-27 Controls IL-17 Production through PD-L1the underlying mechanism of the latter has not been elucidated
(Wang et al., 2007).
Despite its important actions, relatively little was known about
the genes that are directly regulated by IL-27. Herein, we show
that naive T cells express receptors of IL-27. Among the genes
upregulated by IL-27 was Cd274, which encodes PD-L1. IL-
27-dependent induction of PD-L1 on naive cells inhibited IL-17
production in an untreated population of differentiating Th17
cells, and the development of Th17 cell-mediated autoimmune
encephalomyelitis was ameliorated by coadministration of IL-
27-treated naive T cells that express PD-L1. Thus, these data
point to a mechanism by which IL-27 can exert its ability to
suppress IL-17-mediated pathology.
RESULTS
IL-27 Inhibits Early IL-17 Induction
Previous work has shown that IL-27 inhibits Th17 cell differenti-
ation (Batten et al., 2006; Diveu et al., 2009; Stumhofer et al.,
2006). Consistent with these findings, we found that IL-17
production was suppressed when IL-27 was present early in
Th17 cell differentiation (Figure S1A available online). However,
when added 24 hr or later after initial activation, it was in-
effective (Figure S1A). To explain these results, we first consid-
ered that the effects of IL-27 might be a reflection of receptor
expression.
IL-27R comprises a heterodimer consisting of two subunits
encoded by the Il27ra gene and the Il6st gene (Pflanz et al.,
2002, 2004). Consistent with previous work (Chen et al., 2000),
naive T cells express both subunits and Il27ra was downregu-
lated upon activation of CD4+ T cells (Figure S1B). This IL-27R
expression was functional as assessed by IL-27-dependent
STAT activation (Figures S1C–S1E; Stumhofer et al., 2007).
IL-27 readily induced STAT1 activation in naive CD4+ T cells
but induced relatively less STAT3 phosphorylation. This con-
trasted with the action of IL-6, which induced roughly equivalent
levels of STAT1 and STAT3 phosphorylation. In summary, naive
T cells express the IL-27R and functionally respond to this
cytokine.
IL-27-Primed Naive T Cells Inhibit Th17 Cell
Differentiation In trans
Because IL-27 had the capacity to exert its effect on naive CD4+
T cells, we wondered whether it was necessary for IL-27 to
act directly on nascent Th17 cells or whether it could modulate
naive cells that might be able to inhibit development of Th17
cells in trans. Therefore, we primed naive CD45.2+CD4+ T cells
with IL-27 for 3 hr, washed the cells to remove the cytokine,
and then added these cells to naive CD45.1+CD4+ T cells
cultured under Th17 cell-polarizing conditions (Figure S1F). In
the presence of untreated naive CD45.2+CD4+ T cells, more
than 15% of nonprimed CD45.1+CD4+ T cells became IL-17
producers (Figure 1A). When IL-27-primed CD4+ T cells were
added to developing Th17 cells, IL-17 production was signifi-
cantly inhibited (by 40%–60%) (Figures 1A and 1B; p = 0.0062,
two-tailed Student’s t test), regardless of whether the polarizing
conditions were IL-6 and TGF-b or IL-6, IL-1b, and IL-23 (Figures
S1G andS1H). Because we added IFN-g neutralizing antibody to
the Th17 cell-polarizing conditions, this reduction of IL-171018 Immunity 36, 1017–1030, June 29, 2012 ª2012 Elsevier Inc.producers was not due to the ability of IL-27 to promote IFN-g
production (Owaki et al., 2005; Yoshida et al., 2001). Because
IL-6 can also activate STAT1, we assessed the effect of IL-6-
primed naive T cells in trans. Addition of IL-6-primed naive
T cells had no effect on the production of IL-17 by bystander
nascent Th17 cells (CD45.1+CD4+) (Figures 1A and 1B). The inhi-
bition of Th17 cell development by IL-27-primed naive T cells
was also effective when DCs were included (Figures S1I and
S1J). However, global T cell activation was not impaired by
IL-27-primed naive cells, as shown by the fact that proliferation
of bystander CD4+ T cells was unaffected (Figure S1K). Priming
with IL-27 did not influence Th1 cell differentiation as evidenced
by IFN-g production in CD45.1+CD4+ T cells (Figure S1L), indi-
cating that the effect was specific for IL-17 production.
Because it has been reported that the inhibitory effect of
IL-27 on T cell differentiation can be mediated by DCs (Wang
et al., 2007), we wondered whether IL-27 priming of DCs might
also constrain Th17 cell differentiation. However, we found
that this was not the case. In the absence of IL-27-primed
T cells, IL-27 priming of CD11c+ DCs to T cells had no effect
on IL-17 production by CD45.1+CD4+ T cells (Figures S1M
and S1N). Accordingly, we noted minimal expression of Il27ra
on freshly isolated, nonactivated CD11c+ cells (Figure S1O).
Taken together, naive T cells primed with IL-27 can inhibit IL-
17 production, even if the T cells have not been directly exposed
to this cytokine.
IL-27-Primed Naive T Cells Inhibit Th17 Cell
Differentiation In Vivo
To assess whether IL-27-primed naive CD4+ T cells can atten-
uate the development of Th17 cells in vivo, we primed naive
CD45.2+CD4+ T cells from OVA-TCR-transgenic (OT-II) mice
with either IL-27 or no cytokine for 3 hr and transferred these
cells along with unprimed naive CD45.1+ OT-II T cells into
mice. Mice were immunized with OVA peptide and CFA, and
cytokine expression in directly isolated T cells was measured
by intracellular staining 7 days after immunization. Consistent
with our results in vitro, we did not find a difference in the
absolute number of CD45.1+CD4+ T cells that expanded in vivo,
suggesting that proliferation was not impaired (Figure 1C). Im-
portantly though, the relative and absolute numbers of IL-
17-producing CD45.1+ T cells were greatly diminished in mice
that received IL-27-treated naive CD45.2+ T cells, but not in
immunized mice that received unprimed naive CD45.2+ T cells
(Figures 1D and 1E). The effect of IL-27 priming was limited to
Th17 cell differentiation, as shown by the fact that there was
no difference in the relative or total numbers of CD45.1+CD4+
T cells that produced IFN-g (Figure 1F). Thus, naive T cells
primed with IL-27 can exert their inhibitor effect on IL-17 produc-
tion in other T cells in vivo.
Administration of IL-27-Primed Naive CD4+ T Cells
Ameliorates Development of Autoimmune Disease
Based on our findings, we reasoned that exposure of naive
Th cells to IL-27 could be another important mechanism by
which IL-27 acts to limit IL-17-dependent pathology. Therefore,
we next used the model of EAE in which Th17 cells are thought
to be key in terms of immunopathogenesis (Langrish et al.,
2005). We adoptively transferred untreated or IL-27-primed
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Figure 1. IL-27-Primed Cells Inhibit Th17 Cell Differentiation In trans
In brief, naive CD45.2+CD4+ T cells were primed with the indicated cytokines. After washing, cells were mixed with naive CD45.1+CD4+ T cells and cultured with
IL-6, TGF-b, and anti-IFN-g for 3 days.
(A and B) IL-17A and IFN-g production in CD45.1+CD4+ T cells was assessed by intracellular staining. Representative intracellular staining is shown for Th17 cells
(A). Pooled data from six independent experiments are provided in (B) (mean values, NS, not significant).
(C–F) Production of IFN-g and IL-17A in CD45.1+ OT-II CD4+ T cells was analyzed by flow cytometry. Total numbers of CD45.1+ OT-II CD4+ T cells are provided in
(C). Representative results from two individual mice are shown in (D) and pooled data from two independent experiments are provided in (E) and (F) (mean values;
NS, not significant).
Immunity
IL-27 Controls IL-17 Production through PD-L1non-TCR transgenic naive T cells with or without naive TCR
transgenic T cells that recognize MOG peptide (2D2 T cells)
into Rag2/ mice. After transfer, mice were immunized with
MOG and CFA and followed for the development of clinical
signs (Figure S2A). As expected, mice that received primed
T cells alone without transgenic T cells did not develop
disease. Control mice that received unprimed naive T cells
together with naive 2D2 T cells developed severe disease
with an average score of 3.3 (Figure 2A). In sharp contrast,
mice that received IL-27-primed naive T cells together with
2D2 T cells developed a significantly milder disease, mani-
fested by an average score of 2.0 (p < 0.001, two-way
ANOVA). Cumulative disease scores from each mouse also
showed significant decrease in the mice that received IL-27-
primed naive T cells together with 2D2 T cells (Figure S2B;
p < 0.0001, two-tailed Student’s t test). To ascertain thatIL-27 priming was independent of TCR specificity, we primed
OT-II T cells, transferred along with naive 2D2 T cells, and
found that they too limited pathology (Figures S2C and S2D).
Again, consistent with the notion that IL-27-cultured naive cells
did not globally suppress immune responses, the absolute
numbers of CD4+ T cells infiltrating in the CNS were not
significantly different between groups (Figure 2B). Strikingly,
the protection from severe EAE in mice, which received IL-27-
primednaive T cells,was associatedwith significant suppression
in the absolute numbers of IL-17+ T cells in the CNS (Figures 2C,
2D, and S2E; p = 0.0112, two-tailed Student’s t test). In contrast,
the numbers of IFN-g+ T cells, IL-10+ T cells, or FoxP3-express-
ing T cells were not different between the two groups (Figures
2C, 2D, and S2E). These data suggest that IL-27-primed naive
T cells act to selectively inhibit Th17 cell differentiation in vivo
and modulate IL-17-mediated autoimmune disease.Immunity 36, 1017–1030, June 29, 2012 ª2012 Elsevier Inc. 1019
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Figure 2. IL-27-Primed Naive CD4+ T Cells Inhibit Pathogenicity of T Cells In trans
In brief, naive CD4+ T cells were primed with or without IL-27 and transferred with or without sorted naive TCR transgenic 2D2 CD4+ T cells into Rag2/mice to
induce EAE, which were immunized with MOG peptide in CFA.
(A) Data provided represent mean ± SEM of the EAE clinical score of 40 mice pooled from 3 independent experiments (***p < 0.001, *p < 0.05).
(B–D) CNS-infiltrating CD4+ T cells from recipient mice of two groups from (A) were analyzed on day 20 after immunization. Absolute numbers (B), representative
flow cytometric analysis of IL-17A and IFN-g (C), and absolute numbers of subsets of CD4+ T cells (D) are provided from two independent experiments (mean
values; NS, not significant).
Immunity
IL-27 Controls IL-17 Production through PD-L1IL-27 Rapidly Induces PD-L1 Expression on Naive CD4+
T Cells
To define potential mechanisms by which IL-27 priming inhibited
Th17 cell differentiation of nonprimed cells, we analyzed global
gene expression in naive CD4+ T cells stimulated with IL-27 for
3 hr. We found that 375 genes showed a >2-fold difference in un-
stimulated versus IL-27-stimulated naive T cells. Because IL-6
primingwasable to activateSTAT1andSTAT3butwas incapable
of inhibiting Th17 cell differentiation in trans, we compared genes
induced by IL-27 or IL-6. IL-6 stimulation resulted in 648 genes
with a >2-fold difference compared to unstimulated naive
T cells (Figure 3A). One of the genes significantly increased
in IL-27-stimulated cells was Cd274, which encodes PD-L1,
a key immunosuppressive molecule that constrains immune
responses (Table S1; p = 0.0014; Francisco et al., 2010). Of
note, this genewasnot inducedby IL-6 (Figures 3A, 3B, andS3A),
and the expression of other related costimulatory molecules
was not affected (Figure S3A). The ability of IL-27 to induce PD-
L1 at the level of protein expression was confirmed (Figure 3C).
Of note, IL-27 did not induce PD-L1 expression in CD11c+ DCs
(Figure 3D), a cell type that lacks the expression of the Il27ra (Fig-
ure S1O). In contrast, IL-27 enhanced PD-L1 expression on
CD8+ T cells (Figure 3D). In addition, we found no difference in
expression of the immunosuppressive cytokines Il10 or Ebi3,
a component shared by IL-27 or IL-35, between unstimulated
T cells and IL-27-stimulated T cells (Figure S3B). These results1020 Immunity 36, 1017–1030, June 29, 2012 ª2012 Elsevier Inc.indicate that IL-27 rapidly induces PD-L1, affecting naive
T cells but not other subsets.
Requirement for IL-27 Signaling for Optimal Induction
of PD-L1 in T. gondii Infection
To assess the relevance of IL-27 in controlling PD-L1 expression
in vivo, we employed a model in which IL-27 is important for
controlling immunopathology (Villarino et al., 2003). We found
that expression of PD-L1 on CD4+ T cells was significantly lower
in Ebi3/ mice (Figure 3E; p = 0.0182, p = 0.0073, two-tailed
Student’s t test). However, the effect was selective for T cells;
PD-L1 expression on other immune cells remained unaffected
(Figure 3F).
PD-L1 Engagement Underlies the Immunosuppressive
Effect of IL-27-Primed Naive T Cells
We next sought to examine whether the induction of PD-L1
on IL-27-primed naive CD4+ T cells was the principal com-
ponent of the inhibition of bystander Th17 cell differentiation.
To this end, we first investigated the effect of the addition
of neutralizing PD-L1 antibody to cocultures of IL-27-primed
naive CD4+ T cells (CD45.2+) added to developing Th17 cells
(CD45.1+). The addition of PD-L1 neutralizing antibody (Fig-
ure 4A, bottom) completely reversed the effect of IL-27-primed
naive CD4+ T cells to inhibit Th17 cell differentiation in nonprimed
CD4+ T cells (Figures 4A and 4B).
Immunity
IL-27 Controls IL-17 Production through PD-L1To confirm the nonredundant role of PD-L1 in mediating the in
trans inhibition of Th17 cell development by IL-27-primed CD4+
T cells in vivo, we assessed the effect of T cells from mice that
lack this ligand (Latchman et al., 2004). Specifically, untreated
or IL-27-primed CD4+ T cells from wild-type or Cd274/ mice
were transferred along with 2D2 T cells into recipient mice that
were immunized with MOG peptide. As demonstrated before
in Figure 2A, IL-27-primed naive T cells ameliorated EAE severity
(Figures 4C, top, and S4A). Importantly, this protection by IL-
27-primed naive T cells was completely lost in the absence of
PD-L1 (Figures 4C, bottom, and S4A). Although similar numbers
of absolute CD4+ T cells and IFN-g-producers were present
in the CNS in all groups, the number of IL-17 producers
was significantly reduced when IL-27-primed wild-type cells
were administered (Figures 4D–4F; p = 0.0189, two-tailed
Student’s t test). Again, administration of Cd274/ T cells had
no effect on the number of IL-17-producing cells in the CNS
(Figures 4E and 4F).
If the immunosuppressive effect of IL-27 priming was medi-
ated by upregulation of PD-L1, it should be possible to mimic
this effect simply by adding this ligand to differentiating Th17
cells in vitro. Consistent with our hypothesis, we found that inclu-
sion of soluble PD-L1 fusion protein also resulted in suppression
of IL-17 expression comparable to that observed with IL-27
(Figures 5A and 5B). Th17 cell differentiation was not affected
by addition of a control Ig fusion protein (IgG1 Fc). The effect
of soluble PD-L1 during Th17 cell differentiation was specific
for IL-17, as shown by the fact that IFN-g expression in Th1 cells
was not affected by exogenous PD-L1 (Figures 5A and 5B). In
addition, inhibiting PD-1-PD-L1 interactions with neutralizing
antibodies reversed the inhibition of IL-17 production by the
PD-L1 fusion protein (Figures 5C and 5D). In summary, the inhib-
itory effect of IL-27-primed T cells is dependent upon PD-L1
expression.
PD-L1 Engagement Inhibits Th17 Cell Differentiation
Independently of FoxP3
Previous studies have indicated that PD-1-PD-L1 interactions
induce expression of FoxP3 in CD4+ T cells (Francisco et al.,
2009). We therefore considered the possibility that this might
be an explanation underlying the inhibitory effect of PD-L1 on
IL-17 production. However, neither IL-27 nor PD-L1 directly
affected FoxP3 expression in CD4+ T cells cultured under Th17
cell-polarizing conditions (Figures 5A and S5A). To confirm that
PD-L1 exerted its immunoregulatory function independently of
FoxP3, we examined whether PD-L1 inhibited IL-17 production
in T cells from mice with mutation of Foxp3 (Scurfy). Equivalent
inhibitory effects of IL-27 on IL-17 production were evident in
T cells from Scurfy mice, arguing for a FoxP3-independent
mechanism (Figures S5B andS5C). Similarly, the inhibitory effect
of recombinant PD-L1 was the same in cells from wild-type and
Scurfy mice. Thus, PD-L1 engagement inhibits IL-17 production
in a FoxP3-independent manner.
TheCd274Locus IsAccessible inNaiveCD4+ TCells and
Is Directly Regulated by STAT1
We next sought to determine how IL-27 might be acting to regu-
late PD-L1 on naive CD4+ T cells. First, we hypothesized that the
Cd274 gene locus should be accessible in naive Th cells, as indi-cated by the fact that IL-27 rapidly induced PD-L1 expression.
Indeed, by chromatin immunoprecipitation and massive paral-
lel sequencing, we could identify that the Cd274 promoter
was characterized by H3 lysine 4 trimethylation, whereas the
Pdcd1Ig2 promoter did not show this positive epigenetic modi-
fication (Figure S6A; Wei et al., 2009).
Next, because IL-27 induces phosphorylation of STAT1 and
STAT3, we stimulated naive CD4+ T cells from wild-type mice
and mice deficient in STAT1 or STAT3. We found that induction
of Cd274 by IL-27 was completely abolished by the absence of
STAT1 but was unaffected by the absence of STAT3 (Figures 6A,
top, S6B, and S6D). IL-6 had no effect on PD-L1 in Stat1/
T cells (Figure S6C). However, in Stat3/ T cells, in which IL-6
induced unopposed activation of STAT1, this cytokine did
induce expression of PD-L1 (Figures 6A, bottom, S6C, and
S6D). The importance of STAT1 in regulating PD-L1 expression
was confirmed by stimulation of cells with other STAT1-acti-
vating cytokines. Like IL-27, type I and type II interferons induced
PD-L1 expression on naive CD4+ T cells (Figure 6B). However,
the effect of these ligands was not selective; type I and type II
interferons (IFNs) also upregulated PD-L1 expression on cells
that failed to respond to IL-27, including B cells, DCs, and
CD11b+ cells (Figure 6B).
One other important target of STAT1 is Tbx21, which encodes
T-bet, the master regulator of Th1 cells (Lighvani et al., 2001). To
explorewhetherSTAT1 indirectly regulatesPD-L1 through induc-
tionof T-bet,wefirst assessed the inductionofPD-L1 in cells from
mice lacking T-bet. However, we found that this transcription
factor had no effect on induction (Figure S6E). We next investi-
gated the possibility that STAT1 directly binds to the Cd274
promoter in naive T cells. Binding of STAT1 to the Cd274
promoter, which contains GAS and ISRE elements, was noted
after stimulation of cells with IL-27. In contrast, minimal binding
was observed to the Cd274 intronic region (Figure 6C). Thus,
the epigenetic modifications of the Cd274 locus in naive T cells
and the direct binding of IL-27-induced STAT1 help explain the
rapid expression and function of PD-L1 on naive T cells. Because
IFNs inducedPD-L1expressiononnaiveCD4+Tcells (Figure 6B),
wewonderedwhether IFNs, like IL-27, had thecapability to inhibit
Th17 cell differentiation in trans. In fact, we found that IFN-g
priming of T cells inhibited in vitro Th17 cell differentiation to
a similar degree as did IL-27 priming (Figures 6D and 6E). To
assess whether IFN-g-primed naive CD4+ T cells can also limit
IL-17-dependent pathology in vivo, we adoptively transferred
untreated or IFN-g-primed naive CD4+ T cells along with 2D2
T cells into Rag2/ mice, which were immunized with CFA and
MOG peptide. Again, control mice that received unprimed naive
T cells together with naive 2D2 T cells developed severe disease
with an average score of 3.5 (Figures 6F and S6F). In contrast,
mice that received IFN-g-primed naive T cells together with
2D2 T cells developed a significantly milder disease, manifested
by an average score of 1.95 (p < 0.001, two-way ANOVA).
In summary, STAT1 directly binds the Cd274 promoter region
and induces its transcription.
STAT1 Is Critical for Inhibition of Th17 Cell
Differentiation In Vivo by IL-27-Primed Naive T Cells
The in vivo physiological relevance of the STAT1-dependent PD-
L1 induction on naive CD4+ T cells was investigated in amodel ofImmunity 36, 1017–1030, June 29, 2012 ª2012 Elsevier Inc. 1021
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Figure 3. IL-27 Priming Rapidly Induces PD-L1 on Naive CD4+ T Cells
(A–C) Naive CD4+ T cells were cultured in medium alone (control) or stimulated with IL-6 or IL-27 for 3 hr before analyzing differential gene expression by mi-
croarray. The arrow indicates Cd274 expression. Volcano plots depict differential gene expression induced by IL-27 or IL-6 compared to control (A). Comparison
of IL-27- and IL-6-dependent gene expression is shown as a scatter plot (B).
(C and D) Naive CD4+ T cells (C) and naive CD8+ T cells or freshly isolated CD11c+ DCs (D) were stimulated as in (A) and expression of PD-L1 and PD-L2 was
determined by flow cytometry.
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Immunity
IL-27 Controls IL-17 Production through PD-L1systemic inflammation in which IFNs and other cytokines are
elaborated (Karaghiosoff et al., 2003). To this end, we injected
lipopolysaccharide (LPS) into wild-type and STAT1-deficient
mice and assessed the PD-L1 expression. We found that
PD-L1 expression was induced by naive CD4+ T cells after
LPS injection in wild-type mice, but the effect was blocked
in Stat1/ mice (Figures 7A and 7B). To confirm the impor-
tance of STAT1-dependent PD-L1 regulation, we next examined
whether STAT1 was required for the immunosuppressive func-
tion of IL-27-primed naive T cells and their ability to inhibit
bystander cells in trans. We therefore adoptively transferred
IL-27-primed wild-type and Stat1/ naive CD4+ T cells along
with 2D2 T cells into Rag2/mice, which were then immunized
with CFA and MOG peptide. We found that STAT1 deficiency
abrogated the ability of IL-27 priming to attenuate autoimmune
disease (Figures 7C and S7A).
In summary, the ability of IL-27-primed T cells to limit immune-
mediated pathology is dependent upon STAT1.
DISCUSSION
Previous work has established that IL-27 has critical, nonredun-
dant functions as an immunosuppressive cytokine (Batten et al.,
2006; Kastelein et al., 2007; Stumhofer et al., 2006; Villarino et al.,
2003). Herein, we report an unexpected, direct action of IL-27 on
naive Th cells that allows primed cells to limit IL-17-mediated
pathology in trans. Our data show that IL-27 induces PD-L1
in a STAT1-dependent manner, which in turn inhibits Th17
cell differentiation in bystander cells. This effect limits IL-17-
dependent pathology but has no effect on global T cell activation
or Th1 cell differentiation. Thus, the data point to an important
mechanism of action of IL-27.
Multiple mechanisms have been identified by which IL-27 can
suppress immune responses. It is recognized that IL-27 inhibits
Th17 cell differentiation by acting directly upon differentiating
CD4+ T cells via induction of T-bet and downregulation of Rorgt
(Batten et al., 2006; Diveu et al., 2009; Stumhofer et al., 2006).
We found this to be the case as well. There was a trend in reduc-
tion of IL-17 expression in CD4+ T cells exposed to IL-27 for 3 hr.
But we did not examine this further, because direct versus indi-
rect effects could not be discerned. Themechanism described in
the present study is distinct from this mode of inhibition in that
differentiating CD4+ T cells were not directly exposed to IL-27
and yet a profound effect was still noted. In the conditions we
employed, naive T cells were exposed to IL-27, after which the
cytokine was removed, and thus the inhibitory effect of IL-27
was mediated indirectly.
Another immunosuppressive action of IL-27 is mediated by
the production of IL-10 (Batten et al., 2008; Diveu et al., 2009;
Stumhofer et al., 2007). IL-27, in combination with TGF-b, has
been reported to generate IL-10-producing regulatory T cells
characterized by the expression of c-Maf, IL-21, ICOS, and
AhR (Apetoh et al., 2010; Awasthi et al., 2007; Pot et al., 2009).(E and F) Wild-type or Ebi3/ mice were orally administered T. gondii and sacrifi
gated on CD4+, TCR-b+, CD8, and Foxp3 cells. PD-L1 expression is shown as
DCs were gated on CD3, NK1.1, CD19, and CD11chi. B cells are gated on C
separate experiments (mean values; NS, not significant).Our short-term stimulation of IL-27 did not induce IL-10 in naive
CD4+ T cells (Figure S3B); however, this is not to say that IL-27-
induced IL-10 production is not an important part of IL-27’s
action. Nonetheless, in our system the inhibitory effect of IL-27
was largely reversed by elimination of PD-L1 on T cells, arguing
that this is a functionally important mechanism.
One of the striking findings of the present study was that IL-27
rapidly induced PD-L1 on naive CD4+ and CD8+ T cells. To our
knowledge, this has not been recognized previously to be an
action of IL-27. Within 3 hr of exposure to this cytokine, mRNA
of PD-L1 could be seen. Furthermore, we have demonstrated
that this is functionally relevant in blocking IL-17 production
both in vitro and in vivo. The PD-1-PD-L1 pathway is now recog-
nized to be important in the maintenance of peripheral tolerance
(Chen, 2004; Francisco et al., 2010; Freeman et al., 2000).
Mice lacking PD-L1 do not develop spontaneous autoimmune
disease, but its deficiency exacerbates disease in EAE, autoim-
mune arthritis, and autoimmune diabetes (Chen, 2004; Fife et al.,
2006; Hamel et al., 2010; Latchman et al., 2004). The relevance
of this pathway in human disease is substantiated by the asso-
ciation of polymorphisms of CD274 (which encodes PD-L1)
with Graves’ disease and autoimmune Addison’s disease (Hay-
ashi et al., 2008; Mitchell et al., 2009). Conversely, upregulation
of PD-1 in CD8+ T cells contributes to exhaustion of reactive
T cells in mice with chronic viral infection (Barber et al., 2006).
Similarly, high expression of PD-1 by HIV-specific CD8+ T cells
was found in HIV-infected individuals and was associated with
high viral load and exhaustion of HIV-specific CD8+ T cells
(Trautmann et al., 2006).
In some settings, engagement of PD-L1 with PD-1 generates
FoxP3-expressing Treg cells (Francisco et al., 2009). However,
in our system, we saw no evidence of FoxP3 induction either in
naive cells directly primed with IL-27 or in cocultured bystander
cells under Th17 cell-polarizing condition (data not shown).
Multiple stimuli can induce PD-L1 expression on T cells and
antigen-presenting cells. The promoters of the genes encoding
mouse and human PD-L1 exhibit interferon-sensitive response
elements, IFN regulatory factor-1 (IRF-1) binding sites, and
gamma interferon-activated sites (Lee et al., 2006). Accordingly,
PD-L1 can be induced in DCs by type I and type II IFNs
(Schreiner et al., 2004; Yamazaki et al., 2002), although we found
that nonactivated DCs do not express IL-27 receptors and thus
are not responsive to this cytokine basally. As reported herein,
STAT1 activation is of particular importance for PD-L1 upregula-
tion by naive T cells. These data argue that IL-27 is not unique in
its ability to induce PD-L1. In fact, this was the case. We found
that IFNs also induced PD-L1 on naive CD4+ and CD8+ T cells.
Moreover, T cells primed with IFN-g also inhibited Th17 cell
induction in trans, just as did cells primed with IL-27. However,
it is notable that the effect of IL-27 is more circumscribed
compared to type I and type II IFNs. In contrast to IL-27, which
acts predominantly on CD4+ and CD8+ T cells, IFNs induce
PD-L1 expression on a wide variety of cells.ced on day 9. Mesenteric lymph node (mLN) and Peyers patch (PP) cells were
percentages of CD4+ T cells and by geometric mean channel fluorescence (E).
D3, NK1.1, and CD19+ (F). The experiment shown is representative of two
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Figure 4. IL-27-Induced Expression of PD-L1 on Naive CD4+ T Cells Inhibits IL-17 Production In trans
(A and B) Naive CD45.2+CD4+ T cells were primed with IL-6 or IL-27 or cultured in medium alone. After 3 hr, cells were washed and cocultured with naive
CD45.1+CD4+ T cells under Th17 cell-polarizing conditions with an isotype control antibody (top) or PD-L1 antibody (bottom). After 3 days, IL-17A protein
expression of CD45.1+CD4+ T cells was analyzed by intracellular staining. Representative intracellular staining is depicted in (A) and pooled data from four
separate experiments with mean values are shown in (B) (NS, not significant).
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Immunity
IL-27 Controls IL-17 Production through PD-L1Activation of T cells via the antigen receptor also upregulates
PD-L1 expression (Yamazaki et al., 2002). However, the findings
presented in the present study argue that in the course of an
inflammatory immune response, IL-27 can induce PD-L1 upre-
gulation in T cells that are not activated by cognate antigen
and thereby limit immunopathology. With respect to the relative
proportion of bystander cells expressing PD-L1 needed to atten-
uate Th17 cell differentiation of activated CD4 T cells, it is obvi-
ously difficult to directly extrapolate the relevance of in vitro
conditions. Nonetheless, the proportion of naive CD4+ and
CD8+ T cells that can upregulate PD-L1 in response to IL-27
greatly exceed the proportion of antigen-specific CD4 cells.
We also found that the Cd274 promoter was accessible in
naive Th cells, as characterized by the presence of H3 lysine 4
trimethylation associated with the absence of H3 lysine 27
trimethylation, further supporting the notion that PD-L1 can be
rapidly induced. Moreover, our results with T. gondii infection
substantiate the claim that this mechanism is relevant in vivo.
However, this is not to say that induction of PD-L1 on other
cells by other cytokines is irrelevant. This is not the case at all,
because PD-L1 is inducible in a wide variety of cells where it
has critical actions. The present study simply points out that
cytokine-dependent induction of PD-L1 on T cells can influence
the differentiation of antigen-activated CD4+ T cells.
In summary, our study highlights that naive PD-L1+CD4+
T cells induced by IL-27 can limit the effect of pathogenic IL-
17-producing Th17 cells in vitro and in vivo. It is conceivable
that the strategy of IL-27 pretreatment of naive T cells ex vivo
with subsequent adoptive transfer might be used therapeutically
to attenuate autoimmune disease.
EXPERIMENTAL PROCEDURES
Mice and Media
C57BL/6J, B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II, C57BL/6-Tg (Tcra2D2,
Tcrb2D2)1Kuch/J (TCR(2D2)), and B6.129S6-Tbx21tm1Glm/J (Tbx21/) mice
were purchased from Jackson Laboratory; B6.129S6-Rag2tm1Fwa (Rag2/)
mice, B6.SJL-Ptprca/BoyAiTac (CD45.1) mice, and Foxp3sf mice were from
Taconic; and Stat3fl/fl mice were from D. Levy (Lee et al., 2002) and bred
with CD4-Cre+ Tg mice. Stat1/ mice were also from D. Levy (Durbin et al.,
1996). OT-II Tg mice were bred with B6.SJL-Ptprca/BoyAiTac (CD45.1) mice
in our laboratory. FoxP3-enhanced green fluorescent protein (eGFP) reporter
mice have been reported previously (Bettelli et al., 2006). EBI3-deficient
(Ebi3/) mice were from Lexicon Pharmaceuticals, Inc. (The Woodlands,
TX). They were generated by Lexicon Pharmaceuticals for Centocor Research
and Development and provided by Centocor. PD-L1-deficient (Cd274/)
mice were generated by A. Sharpe (Latchman et al., 2004). All animal studies
were performed according to the NIH guidelines for the use and care of live
animals and were approved by the Institutional Animal Care and Use
Committee of NIAMS. All cells were cultured in RPMI medium with 10% (vol/
vol) FCS, 2 mM glutamine, 100 IU ml1 of penicillin, 0.1 mg ml1 of strepto-
mycin, and 20 mM HEPES buffer, (pH 7.2–7.5) (all from Invitrogen) and
2 mM b-mercaptoethanol (Sigma-Aldrich).
Cell Isolation and Differentiation
CD4+ T cells from spleens and lymph nodes of 6- to 8-week-old mice
were purified by negative selection and magnetic separation (Miltenyi Biotec)
followed by sorting of naive CD4+CD62L+CD44CD25 population by(C) Data provided represent mean ± SEM of the EAE clinical score of 32 mice po
(D–F) CNS-infiltrating CD4+ T cells from recipient mice of two groups from
representative flow cytometric analysis of IL-17A and IFN-g (E), and absolute
significant).FACSAria II (BD). For natural T regulatory population, GFP+ cell were sorted
with FACSAria II (BD). CD8+ T cells, B220+ cells, CD11c+ DCs, or CD11b+
macrophages from spleens of 6- to 8-week-old mice were purified by
magnetic separation (Miltenyi Biotec). In some experiments, those cells were
stimulated with IL-6 (20 ng ml1), IL-27 (20 ng ml1), IFN-a (10,000 U ml1),
IFN-b (10,000 U ml1), or IFN-g (20 ng ml1) for 3 hr (all from R&D Systems).
Naive CD4+ T cells were activated by plate-bound anti-CD3 (10 mg ml1;
eBioscience) and soluble anti-CD28 (1 mg ml1; eBioscience) in media for 3
or 4 days either under neutral conditions or with IL-6 (20 ng ml1, R&D
Systems) plus human TGF-b1 (2 ngml1, R&D Systems) and IFN-g neutralizing
antibodies (10 mg ml1, BDPharmingen) for Th17 cell-polarizing condition
or IL-12 (20 ng ml1, R&D Systems) and IL-4 neutralizing antibodies
(10 mg ml1, BioXCell) for Th1 cell-polarizing condition. For coculture experi-
ments, we incubated naive CD45.2+CD4+ T cells with CD45.1+ T cells at
a ratio of one to one, because we found in preliminary experiments that
this was optimal. In some experiments, we added IL-6 (20 ng ml1), IL-27
(20 ng ml1), PD-L1 (5 mg ml1), recombinant human IgG1 Fc (5 mg ml1) (all
from R&D Systems), PD-L1 neutralizing antibody (10 mg ml1, Abcam
(MIH6)), or isotype control antibody (10 mg ml1, Abcam).
Flow Cytometry
Expression of cytokines and transcription factors was assessed by intracel-
lular staining. The following antibodies were used. For cell surface staining:
anti-CD4-PerCPCy5.5, anti-CD4-APC, anti-CD44-FITC or -PE, anti-CD25-
PE, or -APC, anti-Vb5.1/5.2-FITC, anti-Va2-PE, anti-Vb11-FITC, CD45.1-
PerCPCy5.5, anti-PD-L1-PE, anti-PD-L2-PE, and anti-CD3-FITC (all BD).
Anti-CD62L-PE-Cy7, anti-CD11c-PECy7, anti-CD19-eFlour450, and anti-
NK1.1-FITC were purchased from eBioscience. Anti-TCR-b-Alexa Fluor 700
was purchased from BioLegend. Anti-CD8a-PE-Texas Red was purchased
from Abcam. For intracellular staining: anti-IFN-g-FITC, anti-IL-17A-APC,
Foxp3 eFluor450, and anti-FoxP3-FITC (all eBioscience). Anti-IL-4-APC,
anti-IL-10-PE, anti-IFN-g-PE, anti-pSTAT1-Alexa Fluor 647, and anti-
pSTAT3-Alexa Fluor 647 were purchased from BD. For intracellular staining,
cells were stimulated for 4 hr with PMA and ionomycin with the addition of
brefeldin A (GolgiPlug; BD). Afterward, cells were fixed with 4% formyl saline,
permeabilized with 0.1% saponin buffer, and stained with fluorescent anti-
bodies before analyzing on a FACS Calibur (BD). Events were collected and
analyzed with Flow Jo software (Tree Star).
In Vivo Generation of Th17 Cells
Sorted naive CD45.2+ OT-II CD4+ T cells were primed with or without IL-27
(20 ng ml1) for 3 hr. After washing, 5.0 3 105 cells were transferred together
with sorted naive CD45.1+ OT-II CD4+ T cells (1.0 3 105 cells) intravenously
into C57BL/6J mice. After adoptive transfer, recipient mice were immunized
subcutaneously with 50 mg OVA323-339 peptide (Peptides International) in
CFA. Seven days after immunization, spleens were harvested and T cells
were analyzed by flow cytometry for surface marker and intracellular cytokine
production.
Experimental Autoimmune Encephalomyelitis
Sorted naive T cells from C57BL/6J, TCR(OT-II) transgenic, Cd274/, or
Stat1/ mice were primed with or without IL-27 (20 ng ml1) or IFN-g (20 ng
ml1) for 3 hr. After washing, 2.5 3 106 cells were transferred intravenously
together with sorted naive Vb11+ T cells (5.0 3 105 cells) into Rag2/ mice.
After adoptive transfer, recipient mice were immunized subcutaneously with
100 mg MOG35-55 peptide (Peptides International) in CFA on day 0. These
mice were scored daily according to the criteria as described previously (Ghor-
eschi et al., 2010). On day 19 or 20, mononuclear cells were isolated from the
spinal cord of a subset of mice, counted, and analyzed for cytokine expres-
sion. Cumulative disease scores were calculated as the area under the curve
for clinical score of each individual mouse as described previously (Greve
et al., 2004).oled from 2 independent experiments (***p < 0.001, **p < 0.01, *p < 0.05).
(C) were analyzed on day 19 after immunization. Absolute numbers (D),
numbers of subsets of CD4+ T cells (F) are provided (mean values; NS, not
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Figure 5. Soluble PD-L1 Affects Th17 Cell Differentiation
(A and B) Naive CD4+ T cells were cultured with IL-6, TGF-b, and anti-IFN-g (Th17 cell-polarizing conditions, top) or IL-12 and anti-IL-4 (Th1 cell-polarizing
conditions, bottom) for 3 days with PD-L1 or IgG1-Fc as a control. IL-27 and IL-6 were added as additional controls. IL-17A, IFN-g, and FoxP3 protein expression
were analyzed by intracellular staining. Representative flow cytometry plots are depicted in (A) and pooled data from three (Th1 cell-polarizing condition) or four
(Th17 cell-polarizing condition) individual experiments with mean values are shown in (B) (NS, not significant).
(C and D) Naive CD4+ T cells were cultured under Th17 cell-polarizing conditions with PD-L1 or IgG1-Fc in the presence of PD-L1 antibody (bottom) or isotype
control antibody (top) for 3 days. IL-17 and FoxP3 protein expression were analyzed by intracellular staining. Representative intracellular staining is depicted in (C)
and pooled data from three individual experiments with mean values are shown in (D) (NS, not significant).
Immunity
IL-27 Controls IL-17 Production through PD-L1Microarray Data Collection and Analysis
The microarray was performed and analyzed as described previously (Ghor-
eschi et al., 2010). Approximately 10 mg of RNA was labeled and hybridized to
GeneChip Mouse Genome 430 2.0 arrays (Affymetrix) according to the manu-1026 Immunity 36, 1017–1030, June 29, 2012 ª2012 Elsevier Inc.facturer’s protocols. Expression values were determined with GeneChip
Operating Software (GCOS) v1.1.1 and MAS5 method. Downstream analyses
were performed with Partek Genomics Suite software and the statistical
package R.
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Figure 6. Rapid Induction of PD-L1 by IL-27
Is Directly Mediated by STAT1
(A) Naive CD4+ T cells from Stat1/, Stat3/, or
wild-type control mice were stimulated with the
indicated cytokines for 3 hr. Surface expression of
PD-L1 is shown.
(B) Naive CD4+ T cells, freshly isolated CD8+
T cells, B220+ cells, CD11c+ cells, and CD11b+
cells were stimulated with indicated cytokines for
3 hr and expression of PD-L1 was determined by
flow cytometry. Representative data are provided
from two separate experiments.
(C) Naive CD4+ T cells were stimulated with IL-27
for 30 min. Fixed cells were immunoprecipitated
with STAT1 antibody. Eluted DNA was analyzed
by quantitative PCR (mean ± SD). Representative
data are provided from two separate experiments.
(D and E) In brief, naive CD45.2+CD4+ T cells were
primedwith the indicated cytokines. Afterwashing,
cells were mixed with naive CD45.1+CD4+ T cells
and cultured with IL-6, TGF-b, and anti-IFN-g
for 3 days. IL-17A and IFN-g production in
CD45.1+CD4+ T cells was assessedby intracellular
staining. Representative intracellular staining is
shown for Th17 cells (D). Pooled data from three
independent experiments are provided in (E) (mean
values).
(F) Data show mean ± SEM of the EAE clinical
score of 20 mice pooled from 2 independent
experiments (***p < 0.001, **p < 0.01, *p < 0.05).
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Figure 7. STAT1 Is Critical for Induction of
PD-L1 and Inhibition of Th17 Cell Differenti-
ation In Vivo
(A and B) Wild-type or Stat1/ mice received an
intraperitoneal injection of LPS with PBS. One day
after injection, spleens were harvested and CD4+
T cells were analyzed by flow cytometry for PD-L1
expression. Representative results are shown in
(A) and pooled data from two independent exper-
iments are provided in (B) (mean values).
(C) Data show mean ± SEM of the EAE clinical
score of 32 mice pooled from 2 independent
experiments (***p < 0.001, **p < 0.01, *p < 0.05).
Immunity
IL-27 Controls IL-17 Production through PD-L1T. gondii Infections
The ME49 strain of T. gondii was maintained in Swiss Webster and CBA/CaJ,
and tissue cysts were prepared as described (Villarino et al., 2003). For infec-
tions, mice were administered 10 tissue cysts orally and sacrificed within
14 days postinfection. All experiments were conducted according to the
guidelines of the University of Pennsylvania Institutional Animal Care and
Use Committee.Chromatin Immunoprecipitation
ChIP was performed as described previously (Ghoreschi et al., 2010).
Sorted naive CD4+ T cells were activated with or without IL-27
(20 ng ml1) for 30 min followed by cross-linking for 10 min with 1% formal-
dehyde. The cells were harvested and lysed by sonication. After preclearing
with protein A agarose beads (Upstate), cell lysates were immunoprecipi-
tated with anti-STAT1 (Cell Signaling) overnight at 4C. After washing and
elution, cross-links were reversed at 65C for 4 hr. The eluted DNA was
purified, and samples were analyzed by quantitative-PCR with custom-
designed primers and probes via a 7500 real-time PCR system (Applied Bio-
systems). Primers spanning the promoter region of Cd274 and the intronic
region of Cd274 are described in Supplemental Experimental Procedures.
The Ct value of each sample was normalized to the corresponding input
value.LPS Challenge
Mice received an intraperitoneal injection of 1 mg of LPS (Escherichia
coli 0111:B4 LPS; Sigma L2630) in 200 ml of PBS. 18 hr after injection,
T cells isolated from spleens were analyzed by flow cytometry for surface
marker.Statistics
For statistical analysis, all p values in clinical scores of EAE experiments were
calculated with a two-way ANOVA. All others were calculated with a two-tailed
Student’s t test.ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE38375.1028 Immunity 36, 1017–1030, June 29, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
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